U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07246252) titled 'Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects' on Nov. 17.
Brief Summary: A phase 1, randomized, double-blind, parallel group, single-dose study to compare the pharmacokinetics, safety and immunogenicity of two formulations of Omalizumab (Process-Changed CMAB007 and Xolair) in healthy subjects.
Study Start Date: March 28, 2024
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers (HV)
Intervention:
BIOLOGICAL: Process-Changed CMAB007
for subcutaneous injection only
BIOLOGICAL: Xolair (omalizumab)
for subcutaneous injection only
Recruitment Status: COMPLET...